Stock Market Reviews

HRMY (Harmony Biosciences Holdings, Inc.) News

Get the latest news, insights, and market updates on HRMY (Harmony Biosciences Holdings, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
  PLYMOUTH MEETING, Pa., October 23, 2025--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by the following:
  Oct 23, 2025 - $HRMY
• Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates
  Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -22.62% and -57.71%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
  Oct 9, 2025 - $HRMY
• Harmony Biosciences (HRMY): Assessing Valuation After RECONNECT Trial Disappointment for ZYN002 in Fragile X Syndrome
  Harmony Biosciences Holdings (HRMY) is in the spotlight after announcing that its Phase 3 RECONNECT study for ZYN002 in Fragile X syndrome did not meet its main goal, citing higher than expected placebo responses. This update is drawing fresh attention from investors and the biotech sector, given the drug’s prior promise in an area with limited treatment options. See our latest analysis for Harmony Biosciences Holdings. After the recent setback in the RECONNECT study, Harmony Biosciences...
  Oct 2, 2025 - $HRMY
• H.C. Wainwright Reaffirms Buy on Harmony Biosciences Holdings, Inc. (HRMY) Despite Phase 3 Setback
  Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is among the best low-priced growth stocks to buy now. Analysts at H.C. Wainwright have reaffirmed their ‘Buy’ rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), while reducing the price target to $55 from $70, implying a potential upside of nearly 100%. The 21.43% downside in guidance follows the company’s Phase 3 […]
  Sep 29, 2025 - $HRMY
• HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
  Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
  Sep 25, 2025 - $HRMY
• Sector Update: Health Care Stocks Slide Thursday Afternoon
  Health care stocks declined Thursday afternoon, with the NYSE Health Care Index falling 1.8% and the
  Sep 25, 2025 - $HRMY
• Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
  PLYMOUTH MEETING, Pa., September 24, 2025--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). The RECONNECT Study did not meet the primary endpoint of improvement in social avoidance primarily due to a higher than expected placebo response rate.
  Sep 24, 2025 - $HRMY
• Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study
  Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) released topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). Fragile X syndrome is a rare genetic disorder that is the leading known cause of both inherited intellectual disability and autism spectrum disorder. The disorder negatively affects synaptic function, plasticity and neuronal connections, and results in a spectrum of intellectual disabilities and behavioral symptoms,
  Sep 24, 2025 - $HRMY
• Harmony Biosciences Whiffs In 'Undruggable' Genetic Disease; Shares Tumble
  Shares of Harmony Biosciences plunged Wednesday as Fragile X syndrome continued to be "undruggable" for the biotech company.
  Sep 24, 2025 - $HRMY